ENO2 and cancer: In contrast, factors associated with poorer PFS included family history of cancer, ECOG PS of 2, elevated baseline levels of lactate dehydrogenase (LDH), pro-gastrin-releasing peptide (ProGrP), and neuron-specific enolase (NSE) (all P < 0.05).